[Clinical evaluation of the effect of tamsulosin hydrochloride and cernitin pollen extract on urinary disturbance associated with benign prostatic hyperplasia in a multicentered study].
We evaluated the clinical efficacy and safety of tamsulosin hydrochloride and cernitin pollen extract in 243 patients with urinary disturbance associated with benign prostatic hyperplasia. They were assigned randomly to 3 groups, oral tamsulosin hydrochloride, cernitin pollen extract and their combination were administered for 12 weeks. The international prostate symptom score, post-voided residual urine and uroflowmetrogram were obtained before and after treatment. The international prostate symptom score improved in each group and then the maximum flow rate and average flow rate also increased significantly in the tamsulosin hydrochloride-administered groups. In conclusion, the administration of only tamsulosin hydrochloride and the combination of tamsulosin hydrochloride and cernitin pollen extract seemed more effective then the administration of only cernitin pollen extract in the treatment of urinary disturbance associated with benign prostatic hyperplasia.
Aoki
Akihiko
A
Department of Urology, Yamaguchi University School of Medicine.
Naito
Katsusuke
K
Hashimoto
Osamu
O
Yamaguchi
Masatoshi
M
Hara
Yoshihiro
Y
Baba
Yoshikazu
Y
Wada
Takashi
T
Joko
Keiji
K
Nagao
Kazuhiro
K
Yamakawa
Gen-ichiro
G
Suyama
Ken-ichi
K
Nagata
Kazuo
K
Matsuyama
Hideyasu
H
Hirao
Hiroshi
H
Shimizu
Yoshiyuki
Y
Hironaka
Hiroshi
H
Isoyama
Riichiro
R
Takemoto
Masahiko
M
Tuchida
Masahiro
M
Shiraishi
Kazutaka
K
Kato
Masahisa
M
Kamiryo
Yoriaki
Y
Harada
Hiroyuki
H
Otsuka
Tomoaki
T
Mitsui
Hiroshi
H
Nasu
Takashi
T
Hayashida
Shigeaki
S
Jojima
Kazutaka
K
Sacho
Toshiaki
T
Koshido
Yoshikazu
Y
Harada
Noriaki
N
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000368:Aged; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D006801:Humans; D008297:Male; D008875:Middle Aged; D010936:Plant Extracts / Q000627:therapeutic use*; D011470:Prostatic Hyperplasia / Q000150:complications*; D012434:Secale; D013449:Sulfonamides / Q000627:therapeutic use*; D000077409:Tamsulosin; D014555:Urination Disorders / Q000188:drug therapy* / Q000209:etiology
D000317:Adrenergic alpha-Antagonists; D010936:Plant Extracts; D013449:Sulfonamides; C010070:cernilton; D000077409:Tamsulosin